Title : How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.

Pub. Date : 2005 Oct 15

PMID : 16243802






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Tamoxifen ADAM metallopeptidase domain 9 Homo sapiens
2 Although estrogen receptor levels lost their predictive power for this group of patients, high levels of ADAM-9 (OR, 1.59; P = 0.007) and ADAM-11 (OR, 1.65; P = 0.001) were significantly associated with a higher efficacy of tamoxifen therapy. Tamoxifen ADAM metallopeptidase domain 9 Homo sapiens
3 CONCLUSIONS: Our results show that especially for primary tumors containing stromal elements, the assessment of mRNA expression levels of ADAM-9 and ADAM-11 could be useful to identify patients with recurrent breast cancer who are likely to benefit or fail from tamoxifen therapy. Tamoxifen ADAM metallopeptidase domain 9 Homo sapiens